相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-Dose Oritavancin Versus 7-10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study
G. Ralph Corey et al.
CLINICAL INFECTIOUS DISEASES (2015)
Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections
Joseph S. Solomkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline
A. B. Macone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia
Chung-Chih Lai et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial
Gregory J. Moran et al.
LANCET INFECTIOUS DISEASES (2014)
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Helen W. Boucher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Successful Ertapenem-Doripenem Combination Treatment of Bacteremic Ventilator-Associated Pneumonia Due to Colistin-Resistant KPC-Producing Klebsiella pneumoniae
Giancarlo Ceccarelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae
Helen Giamarellou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens
J. A. Sutcliffe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)
Ronald N. Jones et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2013)
Aminoglycoside therapy in infectious diseases
Panagiotis Poulikakos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci
Russell Hope et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections The ESTABLISH-1 Randomized Trial
Philippe Prokocimer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011
Ian Morrissey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L. Silvia Munoz-Price et al.
LANCET INFECTIOUS DISEASES (2013)
Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive Klebsiella pneumoniae
Kenneth S. Thomson
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Comparative Efficacies of Human Simulated Exposures of Tedizolid and Linezolid against Staphylococcus aureus in the Murine Thigh Infection Model
R. A. Keel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria
Elizabeth B. Hirsch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic
Trudy H. Grossman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Unmet Medical Need in Infectious Diseases
Adam L. Hersh et al.
CLINICAL INFECTIOUS DISEASES (2012)
Ceftaroline Fosamil: A Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureus
Henry Poon et al.
CLINICAL THERAPEUTICS (2012)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
George G. Zhanel et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2012)
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia
Douglas J. Biedenbach et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
Susan C. Nicholson et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections
Martin E. Stryjewski et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization
Joan M. Remy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece
Irene Galani et al.
JOURNAL OF CHEMOTHERAPY (2012)
Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
Roger B. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The crisis of no new antibiotics-what is the way forward?
Laura J. V. Piddock
LANCET INFECTIOUS DISEASES (2012)
Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
Konstantinos A. Polyzos et al.
PLOS ONE (2012)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
Candace Y. Hooper et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2012)
The oxazolidinones: past, present, and future
Karen Joy Shaw et al.
ANTIMICROBIAL THERAPEUTICS REVIEWS: ANTIBIOTICS THAT TARGET THE RIBOSOME (2011)
Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus
Sandrine Lemaire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Antimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria
Chau Minh Tran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Pharmacodynamics of Razupenem (PZ601) Studied in an In Vitro Pharmacokinetic Model of Infection
Alasdair P. MacGowan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions
Will Stubbings et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Carbapenems: Past, Present, and Future
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
Neil Gupta et al.
CLINICAL INFECTIOUS DISEASES (2011)
Telavancin versus Vancomycin for HospitalAcquired Pneumonia due to Gram-positive Pathogens
Ethan Rubinstein et al.
CLINICAL INFECTIOUS DISEASES (2011)
In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study
Andrew Walkty et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study
James A. Karlowsky et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae
Emilia Titelman et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa
Souha S. Kanj et al.
MAYO CLINIC PROCEEDINGS (2011)
Hydrolysis and Inhibition Profiles of beta-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem
Anne Marie Queenan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vivo Pharmacodynamic Activity of Tomopenem (formerly CS-023) against Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus in a Murine Thigh Infection Model
Kiyoshi Sugihara et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Activity of the Investigational Fluoroquinolone Finafloxacin against Ciprofloxacin-Sensitive and -Resistant Acinetobacter baumannii Isolates
Paul G. Higgins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Comparative In Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates
Tsai-Ling Lauderdale et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
A Multicenter, Randomized Controlled Clinical Study on Biapenem and Imipenem/Cilastatin Injection in the Treatment of Respiratory and Urinary Tract Infections
Bei Jia et al.
CHEMOTHERAPY (2010)
The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
David N. Gilbert et al.
CLINICAL INFECTIOUS DISEASES (2010)
Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin-Structure Infection
G. Ralph Corey et al.
CLINICAL INFECTIOUS DISEASES (2010)
Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community-Acquired Pneumonia
Thomas M. File et al.
CLINICAL INFECTIOUS DISEASES (2010)
Besifloxacin: A Topical Fluoroquinolone for the Treatment of Bacterial Conjunctivitis
Mei H. Chang et al.
CLINICAL THERAPEUTICS (2010)
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results
Shannon D. Putnam et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Current Epidemiology of Multidrug-Resistant Gram-Negative Bacilli in the United States
Alexander J. Kallen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008)
Rodrigo E. Mendes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia
Michael A. Pfaller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2009)
Doripenem Monohydrate, A Broad-Spectrum Carbapenem Antibiotic
S. James Matthews et al.
CLINICAL THERAPEUTICS (2009)
The role of telavancin in the treatment of MRSA infections in hospital
Matteo Bassetti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era
Frank R. DeLeo et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens
Laura Lawrence et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections
Gary J. Noel et al.
CLINICAL INFECTIOUS DISEASES (2008)
Population Pharmacokinetics of Tebipenem Pivoxil (ME1211), a Novel Oral Carbapenem Antibiotic, in Pediatric Patients with Otolaryngological Infection or Pneumonia
Nobuo Sato et al.
DRUG METABOLISM AND PHARMACOKINETICS (2008)
Dalbavancin and telavancin:: novel lipoglycopeptides for the treatment of Gram-positive infections
George G. Zhanel et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2008)
Clinical and economic impact of common multidrug-resistant gram-negative bacilli
Christian G. Giske et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Interactions of ceftobiprole with β-lactamases from molecular classes A to D
Anne Marie Queenan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Systematic review: fluoroquinolones for the treatment of intra-abdominal surgical infections
M. E. Falagas et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity
Levita K. Hidayat et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone
Hee-Soo Park et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
LE Jauregui et al.
CLINICAL INFECTIOUS DISEASES (2005)
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
HS Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem
T Koga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Activity of the new quinolone WCK 771 against pneumococci
PC Appelbaum et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects
JP Shaw et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms
LS Almer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy
PA Moise-Broder et al.
CLINICAL INFECTIOUS DISEASES (2004)
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia
G Sakoulas et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent
EJ Kim et al.
DRUG AND CHEMICAL TOXICOLOGY (2004)
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone
AM Nilius et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria
EJC Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone
T Yamakawa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
New uses for new and old quinolones and the challenge of resistance
DC Hooper
CLINICAL INFECTIOUS DISEASES (2000)
分享论文
